{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:59:38Z","timestamp":1792839578994,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3591,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>\n                           <jats:bold>Abstract<\/jats:bold>\n                        <\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>This placebo-controlled, randomized, multicenter trial compared the effects of MTX plus UDCA to UDCA alone on the course of primary biliary cirrhosis (PBC). Two hundred and sixty five AMA positive patients without ascites, variceal bleeding, or encephalopathy; a serum bilirubin less than 3 mg\/dL; serum albumin 3 g\/dL or greater, who had taken UDCA 15 mg\/kg daily for at least 6 months, were stratified by Ludwig's histological staging and then randomized to MTX 15 mg\/m2 body surface area (maximum dose 20 mg) once a week while continuing on UDCA. The median time from randomization to closure of the study was 7.6 years (range: 4.6-8.8 years). Treatment failure was defined as death without liver transplantation; transplantation; variceal bleeding; development of ascites, encephalopathy, or varices; a doubling of serum bilirubin to 2.5 mg\/dL or greater; a fall in serum albumin to 2.5 g\/dL or less; histological progression by at least two stages or to cirrhosis. Patients were continued on treatment despite failure of treatment, unless transplantation ensued, drug toxicity necessitated withdrawal, or the patient developed a cancer. There were no significant differences in these parameters nor to the time of development of treatment failures observed for patients taking UDCA plus MTX, or UDCA plus placebo. The trial was conducted with a stopping rule, and was stopped early by the National Institutes of Health at the advice of our Data Safety Monitoring Board for reasons of futility.<\/jats:bold>\n                                 <jats:underline>In conclusion<\/jats:underline>\n                                 <jats:bold>, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone.<\/jats:bold>\n                                 <jats:bold>\n                                    Supplementary material for this article can be found on the Hepatology website\n                                 <\/jats:bold>\n                                 <jats:bold>(<\/jats:bold>\n                                 http:\/\/www.interscience.wiley.com\/jpages\/0270-9139\/suppmat\/index.html\n                                 <jats:bold>). (Hepatology 2005;42:1184\u20131193.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20897","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T01:17:09Z","timestamp":1130289429000},"page":"1184-1193","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":105,"title":["Methotrexate (MTX) Plus Ursodeoxycholic Acid (UDCA) in the Treatment of Primary Biliary Cirrhosis * #"],"prefix":"10.1097","volume":"42","author":[{"given":"Burton","family":"Combes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott S.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Flye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago J.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velimir A.","family":"Luketic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"McCashland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowen K.","family":"Zetterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Di Bisceglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent G.","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Carithers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Rosoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Bonacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney S.","family":"Markin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Contos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-25-20250207","first-page":"240","article-title":"Die Wirkung von Ursodeoxycholsaeure bei chronischen Lebererkrankungen. Eine Pilotstudie.","volume":"23","author":"David","year":"1985","journal-title":"Z Gastroenterologie"},{"key":"R3-25-20250207","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis.","volume":"324","author":"Poupon","year":"1991","journal-title":"New Engl J Med"},{"key":"R4-25-20250207","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Doubleblind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"R5-25-20250207","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"R6-25-20250207","first-page":"759","article-title":"A randomized, doubleblind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"R7-25-20250207","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-109-5-429","article-title":"Primary biliary cirrhosis treated with lowdose oral pulse methotrexate.","volume":"109","author":"Kaplan","year":"1998","journal-title":"Ann Intern Med"},{"key":"R8-25-20250207","first-page":"757","article-title":"Methotrexate treatment of chronic cholestatic liver disease: friend or foe.","volume":"268","author":"Kaplan","year":"1989","journal-title":"Quart J Med"},{"key":"R9-25-20250207","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/0016-5085(91)90085-Y","article-title":"Treatment of primary biliary cirrhosis with lowdose weekly methotrexate.","volume":"101","author":"Kaplan","year":"1991","journal-title":"Gastroenterology"},{"key":"R10-25-20250207","first-page":"295","article-title":"Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis.","volume":"91","author":"Bergasa","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"R11-25-20250207","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-8278(05)80004-2","article-title":"Positive response to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone.","volume":"18","author":"Buscher","year":"1993","journal-title":"J Hepatol"},{"key":"R12-25-20250207","first-page":"1158","article-title":"The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.","volume":"22","author":"Lindor","year":"1995","journal-title":"Hepatology"},{"key":"R13-25-20250207","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A"},{"key":"RU16-25-20250207","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2307\/2531692","article-title":"Symmetric group sequential designs.","volume":"45","author":"Emerson","year":"1989","journal-title":"Biometrics"},{"key":"RU17-25-20250207","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.0006-341X.2003.00090.x","article-title":"Flexible implementation of group sequential stopping rules using constrained boundaries.","volume":"59","author":"Burington","year":"2003","journal-title":"Biometrics"},{"key":"RU18-25-20250207","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/biomet\/77.4.875","article-title":"Parameter estimation following group sequential hypothesis testing.","volume":"77","author":"Emerson","year":"1990","journal-title":"Biometrika"},{"key":"R19-25-20250207","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0016-5085(94)90085-X","article-title":"Interstitial pneumonitis after low dose methotrexate therapy in primary biliary cirrhosis.","volume":"107","author":"Sharma","year":"1994","journal-title":"Gastroenterology"},{"key":"R20-25-20250207","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-2275(20)38684-3","article-title":"High pressure liquid chromatographic analysis of conjugated bile acids in human bile; simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids.","volume":"28","author":"Rossi","year":"1987","journal-title":"J Lipid Res"},{"key":"R21-25-20250207","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/17843286.1996.11718480","article-title":"Combined treatment with methotrexate and ursodeoxycholic acid in noncirrhotic primary biliary cirrhosis.","volume":"51","author":"Van Steenbergen","year":"1996","journal-title":"Acta Clin Belgica"},{"key":"R22-25-20250207","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-8278(97)80294-2","article-title":"The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.","volume":"27","author":"GonzalezKoch","year":"1997","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20897","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200511000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:04:49Z","timestamp":1738944289000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200511000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20897","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}